Coronary revascularization in end-stage renal disease

Area of Science:

• Cardiology
• Nephrology
• Vascular Medicine

Background:

• End-stage renal disease (ESRD) patients have high mortality from coronary artery disease and acute cardiac events.
• These patients are often referred for coronary revascularization but are typically excluded from clinical trials.
• This exclusion limits evidence-based decision-making due to differing risk-benefit ratios in the ESRD population.

Purpose of the Study:

• To review current literature on morbidity, mortality, and outcomes of coronary revascularization in dialysis patients.
• To evaluate the impact of advanced therapeutic options, including drug-eluting stents, on outcomes.

Main Methods:

• Systematic review of existing studies and database analyses.
• Analysis of outcomes data for surgical and percutaneous coronary revascularization in end-stage renal disease patients.
• Inclusion of data on the use and efficacy of drug-eluting stents.

Main Results:

• Data suggests that coronary revascularization outcomes in dialysis patients differ significantly from the general population.
• The addition of drug-eluting stents may alter the risk-benefit profile, but requires further investigation.
• Retrospective analyses form the basis for current clinical decisions.

Conclusions:

• Clinical decisions for coronary revascularization in end-stage renal disease patients must account for their unique pathophysiology and outcomes.
• Further research is needed to establish optimal revascularization strategies and the role of new technologies like drug-eluting stents in this high-risk group.